Luetkens Tim, Yousef Sara, Radhakrishnan Sabarinath Venniyil, Atanackovic Djordje
Oncology (Williston Park). 2017 Jan 15;31(1):55-63.
The introduction of cellular immunotherapies using genetically modified T cells has revolutionized the treatment of patients with B-cell lymphomas. However, despite the progress made in this field, similarly effective immunotherapeutic approaches have not yet been identified for patients with solid tumors or other hematologic malignancies such as multiple myeloma. Here we outline the most promising novel cellular immune strategies for patients with multiple myeloma. In addition, we highlight combinatorial approaches that, it is hoped, will further optimize cellular immunotherapies for myeloma and lead to deep and durable responses and, possibly, even cures.
使用基因改造T细胞的细胞免疫疗法的引入彻底改变了B细胞淋巴瘤患者的治疗方式。然而,尽管该领域取得了进展,但对于实体瘤患者或其他血液系统恶性肿瘤(如多发性骨髓瘤)患者,尚未确定类似有效的免疫治疗方法。在此,我们概述了针对多发性骨髓瘤患者最有前景的新型细胞免疫策略。此外,我们强调了联合治疗方法,希望这些方法将进一步优化骨髓瘤的细胞免疫疗法,带来深度且持久的反应,甚至可能实现治愈。